Eitan Kugler, MD PhD
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | Tel-Aviv University, Tel-Aviv, IL, Human Molecular Genetics and Biochemistry, Doctor of Philosophy (PhD) |
| 2008 | Ben Gurion University, Beer Sheba, IL, Doctor of Medicine (MD) |
Postgraduate Training
| 2023-2024 | Leukemia Fellowship, Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2020-2022 | Resident, Hematology, Rabin Medical Center, Davidoff Cancer Center, Tel-Aviv University, Petah-Tikva |
| 2014-2019 | PhD Student, Human Molecular Genetics and Biochemistry, Tel-Aviv University, Tel-Aviv |
| 2009-2013 | Resident, Internal Medicine, Rabin Medical Center, Tel-Aviv University, Petah-Tikva |
| 2008-2009 | Intern, Sheba Medical Center, Tel-Aviv University, Ramat-Gan |
Board Certifications
| 2022 | Hematology, Israel medical association |
| 2013 | Internal Medicine, Israel medical association |
| 2008 | Licensing Examination part II, Ministry of Health, Israel |
| 2007 | Licensing Examination part I, Ministry of Health, Israel |
Experience & Service
Administrative Appointments/Responsibilities
Resident Representative, Department of Internal Medicine Division Rabin Medical Center,, Tel-Aviv University, Petah-Tikva, 2009 - 2013
Honors & Awards
| Best Tutor for Medical Students Award, Ben Gurion University, Faculty of Health Science, Beer Sheba, Israel | |
| Board Certified in Internal medicine, Israel Medical Association | |
| Selected for the 9th German-Israeli Cancer Research School on cancer stem cells and tumor heterogeneity, Joint Scientific Committee of the German Cancer Research Center (DKFZ) and the Israeli ministry of science | |
| Selected for “Bareket" training program, “Clalit” Health Organization | |
| Rothschild scholarship |
Selected Publications
Peer-Reviewed Articles
- Braish JS, Kugler E, Jabbour E, Woodman K, Ravandi F, Nicholas S, Jain N, Kantarjian H, Sasaki K. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(11):783-788, 2024. PMID: 39013740.
- Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, Canaani J, Moshe Y, Krayem B, Aumann S, Henig I, Vainstein V, Shargian L, Ganzel C, Yeshurun M, Levi I, Raanani P, Akria L, Ofran Y, Shimony S, Wolach O. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. Br J Haematol 205(3):932-941, 2024. PMID: 38782575.
- Kugler E, Madiwale S, Yong D, Thoms JAI, Birger Y, Sykes DB, Schmoellerl J, Drakul A, Priebe V, Yassin M, Aqaqe N, Rein A, Fishman H, Geron I, Chen CW, Raught B, Liu Q, Ogana H, Liedke E, Bourquin JP, Zuber J, Milyavsky M, Pimanda J, Prive GG, Izraeli S. The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG. Nature communications 14(1):5871, 2023. PMID: 37735473.
- Rein A, Geron I, Kugler E, Fishman H, Gottlieb E, Abramovich I, Giladi A, Amit I, Mulet-Lazaro R, Delwel R, Groschel S, Levin-Zaidman S, Dezorella N, Holdengreber V, Rao TN, Yacobovich J, Steinberg-Shemer O, Huang QH, Tan Y, Chen SJ, Izraeli S, Birger Y. Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency. Haematologica 108(9):2316-2330, 2023. PMID: 36475518.
- Goldberg I, Cohen E, Gafter-Gvili A, Shochat T, Kugler E, Margalit I, Goldberg E, Raanani P, Krause I. A Longitudinal Assessment of the Natural Change in Haemoglobin, Haematocrit, and Mean Corpuscular Volume with Age. Acta haematologica 146(3):206-213, 2023. PMID: 36724761.
- Kugler, E, Madiwale, S, Yong, D, Birger, Y, Thoms, JA, Sykes, DB, Yassin, M, Aqaqe, N, Rein, A, Fishman, H, Geron, I, Chen, CW, Raught, B, Liu, Q, Milyavsky, M, Pimanda, JE, Privé, GG, Izraeli, S. AML-131 ERG. Clinical Lymphoma, Myeloma and Leukemia 22:S215-S216, 2022. PMID: None.
- Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Ann Hematol 101(9):2001-2010, 2022. PMID: 35739428.
- Fishman H, Madiwale S, Geron I, Bari V, Van Loocke W, Kirschenbaum Y, Ganmore I, Kugler E, Rein-Gil A, Friedlander G, Schiby G, Birger Y, Strehl S, Soulier J, Knoechel B, Ferrando A, Noy-Lotan S, Nagler A, Mulloy JC, Van Vlierberghe P, Izraeli S. ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood 139(3):399-412, 2022. PMID: 34624096.
- Ling T, Birger Y, Stankiewicz MJ, Ben-Haim N, Kalisky T, Rein A, Kugler E, Chen W, Fu C, Zhang K, Patel H, Sikora JW, Goo YA, Kelleher N, Zou L, Izraeli S, Crispino JD. Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis. Blood 134(19):1619-1631, 2019. PMID: 31409672.
- Aqaqe N, Yassin M, Yassin AA, Ershaid N, Katz-Even C, Zipin-Roitman A, Kugler E, Lechman ER, Gan OI, Mitchell A, Dick JE, Izraeli S, Milyavsky M. An ERG Enhancer-Based Reporter Identifies Leukemia Cells with Elevated Leukemogenic Potential Driven by ERG-USP9X Feed-Forward Regulation. Cancer Res 79(15):3862-3876, 2019. PMID: 31175119.
- Yassin M, Aqaqe N, Yassin AA, van Galen P, Kugler E, Bernstein BE, Koren-Michowitz M, Canaani J, Nagler A, Lechman ER, Dick JE, Wienholds E, Izraeli S, Milyavsky M. A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity. Leukemia 33(8):2061-2077, 2019. PMID: 30705411.
- Kugler E, Cohen E, Goldberg E, Nardi Y, Levi A, Krause I, Garty M, Krause I. C reactive protein and long-term risk for chronic kidney disease: a historical prospective study. J Nephrol 28(3):321-7, 2015. PMID: 24981713.
- Kugler E, Levi A, Goldberg E, Zaig E, Raanani P, Paul M. The association of central venous catheter placement timing with infection rates in patients with acute leukemia. Leuk Res 39(3):311-3, 2015. PMID: 25636357.
- Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L, Lahav M, Yeshurun M, Shpilberg O, Herscovici C, Wolach O, Itchaki G, Bar-Natan M, Vidal L, Gafter-Gvili A, Raanani P. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. Am J Hematol 89(3):243-8, 2014. PMID: 24178750.
- Kugler E, Shoham-Vardi I, Burstien E, Mazor M, Hershkovitz R. The safety of a trial of labor after cesarean section in a grandmultiparous population. Arch Gynecol Obstet 277(4):339-44, 2008. PMID: 17957377.
Other Articles
- Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis. Annals of Hematology 101(9):2011, 2022. PMID: 35869985.
- Mizrahi N, Kugler E, Hayman L, Yeshurun M, Grossman A, Raanani P, Wolach O T-Lymphoblastic Leukemia/Lymphoma and Thymoma: A Case Report and Review of the Literature of a Rare Association. Acta Haematol 145(1):106-111, 2022. PMID: 34537764.
- Mouallem M, Zemer-Wassercug N, Kugler E, Sahar N, Shapira-Frommer R, Schiby G Tumor lysis syndrome and malignant melanoma. Med Oncol 30(3):364, 2013. PMID: 23673985.
Editorials
- Kugler E. Charting a path through resistance: histone deacetylase inhibitors for TP53-mutated B-cell acute lymphoblastic leukemia. Haematologica 109(6):1643-1645, 2024. PMID: 38356461.
Selected Presentations & Talks
International Presentations
- 2024. Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis. Poster. ASH 2024. San Diego, US.
- 2024. Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission. Poster. ASH 2024. San Diego, US.
- 2024. Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant. Poster. ASH Annual Meeting 2024. San Diego, US.
- 2022. A single amino acid at PNT domain of ERG mediates its leukemogenic activity through interaction with the NCoR-HDAC3 co-repressor complex. Poster. 2022 European Hematology Association (EHA) Congress. Vienna, AT.
- 2020. The PNT Domain of ERG Regulates Hematopoietic Stemness and is Required for the Maintenance of ERG-Induced Leukemia. Poster. 2020 Society of Hematologic Oncology. Houston, US.
- 2018. THE PNT DOMAIN OF ERG REGULATES HEMATOPOIETIC STEMNESS, YET IS NOT ESSENTIAL FOR ERG INDUCED ACUTE MYELOID LEUKEMIA. Poster. 23rd European Hematology Association Congress. Stockholm, SE.
- 2017. Oral presentation. None. Bi-annual leukemia meeting. Rehovot, IL.
Formal Peers
- 2022. Diagnosis and management of AML in adults: 2022 ELN recommendations. Petah Tikva, IL.
- 2021. Lipoprotein A and hypercoagulability. Petah Tikva, IL.
- 2021. Gilteritinib in Relapsed and Refractory AML: Updates from the EHA 2021 Conference. Petah Tikva, IL.
- 2020. Hodgkin Lymphoma. Petah Tikva, IL.
- 2020. Characterizing the Functionality of a Mutated Form of ERG to Uncover its Leukemogenic Pathway. Tel-Aviv, IL.
- 2020. DOACs in Patients with Obesity. Petah Tikva, IL.
- 2017. The PNT Domain of ERG Regulates Hematopoietic Stemness and is Required for the Maintenance of ERG-Induced Leukemia. Rehovot, IL.
- 2016. The Role of the PNT Domain of ERG in Leukemogenesis. Tel-Aviv, IL.
Grant & Contract Support
| Title: | The Varda and Boaz Dotan Research Center in Hematology-oncology, |
| Funding Source: | Varda and Boaz Dotan Research Center |
| Role: | PI |
Patient Reviews
CV information above last modified January 31, 2025